The grapefruit: An old wine in a new glass? Metabolic and cardiovascular perspectives

Cardiovascular Journal of Africa

Volumn 21, Issue 5, 2010, Pages 280-285

  Owira, Peter M O ^a   Ojewole, John A O ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Cardiovascular disease; Diabetes mellitus; Drug interactions; Grapefruit juice; Hesperidin; Naringin

Indexed keywords

AMLODIPINE; ATORVASTATIN; AURANTIIN; BERGAMOTTIN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CILOSTAZOL; CYTOCHROME P450 3A4; DILTIAZEM; ETHINYLESTRADIOL; FELODIPINE; FLAVONOID; FUROCOUMARIN; GLYCOPROTEIN P; GRAPEFRUIT EXTRACT; HESPERIDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; NARINGENIN; NIFEDIPINE; NIMLODIPINE; NISOLDIPINE; NITRENDIPINE; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL;

AGARISU BISPORUS; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENTIATION; FLUSHING; FOOD DRUG INTERACTION; FUNGUS; GENETIC POLYMORPHISM; GLUCOSE HOMEOSTASIS; HUMAN; HYPOTENSION; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MONASCUS PUPUREUS; MORCHELLA ESCULENTA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PHYTOCHEMISTRY; PLEURATUS SAPIDUS; PURPURA; QT PROLONGATION; RAT; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TACHYCARDIA; ULTRAVIOLET IRRADIATION; VEIN THROMBOSIS; VOLUNTEER;

BEVERAGES; CARDIOVASCULAR DISEASES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS; FLAVANONES; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINES; METABOLIC SYNDROME X; PHYTOTHERAPY;

EID: 78650819385     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007; 3: 33.
2. Moore GA. Oranges and lemons: clues to the taxonomy of citrus from molecular markers. Trend Genet 2001; 17(9): 536-540.
3. E. Nicolosi E, Deng ZN, Gentile A, Malfa SJ, Continella G, Tribulato E. Citrus phylogeny and genetic origin of important species as investigated by molecular markers. TAG Theoret Appl Genet 2000; 100: 1155-1166.
4. Gmitter FG (jun). Origin, evolution and breeding of the grapefruit. Pl Breed Rev 1995; 13: 345-363.
5. Jayapaskasha GK, Girennavar B, Patil BS. Radical scavenging activities of Rio Red grapefruits and sour orange fruit extracts in different in vitro model systems. Bioresource Technol 2008; 99: 4484-4494. (Pubitemid 351380837)
6. De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem, 2006; 54: 249-255.
7. Benavente-Garcia O, Castillo J. Updates on uses and properties of Citrus flavonoids: new findings in anticancer, cardiovascular and anti-inflammatory activity. J Agric Food Chem 2008; 56: 6185-6205.
8. Girennavar B, Jayaprakasha GK, Patil BS. Influence of pre- and postharvest factors and processing on the levels of furocoumarins in grapefruits. Food Chem 2008; 111: 387-392.
9. Gorski C, Huang SM, Pinto A, Hamman MA, Janna K, Hilligoss JK, et al. The effect Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Therapeut 2004; 75(1): 89-100.
10. Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS. Antioxidant activity of citrus limonoids, flavonoids and coumarins. J Agric Food Chem 2005; 53(6): 2009-2014.
11. Dwivedi C, Heck WJ, Downie AA, Larroya S, Webb TE. Effect of calcium glucarate on beta-glucoronidase activity and glucarate content of certain vegetables and fruits. Biochem Med Metab Biol 1990; 43(2): 83-92. (Pubitemid 20175780)
12. Ribeiro IA, Ribeiro MHL. Naringing and naringenin determination and control in grapefruit juice by a validated HPLC method. Food Control 2008; 19: 432-438.
13. Grande LA, Mendez RD, Krug R, Verschuyl EJ. Attention-grapefruit. Lancet 2009; 373: 122.
14. Saito, Mitsuo S, Mutsuko HK, Mariko M, Tsutomu U, Ryuichi H. Undesirable effects of citrus juice on pharmacokinetics of drugs: focus on recent studies. Drug Safety 2005; 28: 677-694.
15. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12(6): 357-362.
16. Pillai U, Muzaffar J, Sen S, Yancey A. Grapefruit juice and verapamil: a toxic cocktail. South Med J 2009; 102: 308-309.
17. Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharm Ther 1993; 54: 589-594. (Pubitemid 24028441)
18. Fuhr U, Maier-Brüggemann A, Blume H, Mück W, Unger S, Kuhlmann J, et al. Grapefruit juice increases oral nimlodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36: 126-132.
19. Odou P, Ferrari N, Barthélémy C, Brique S, Lhermitte M, Vincent A, et al. Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther 2005; 30(2): 153-158. (Pubitemid 41583610)
20. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189-193.
21. Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and hemodynamics of amlodipine. Br J Clin Pharmacol 2000; 50: 455-463.
22. Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Role of furanocoumarin derivatives in grapefruit juice-mediated inhibition of human CYP3A4 activity. Drug Metab Dispos 2000; 28: 766-771.
23. Kakar SM, Paine MF, Stewart PW, Watkins PB. 6′,7′- dihydroxybergamottin contributes to the grapefruit effect. Clin Pharmacol Ther 2004; 75: 569-579.
24. Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 2004; 76(6): 607-617. (Pubitemid 39601550)
25. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553.
26. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Pharmacol Exp Ther 1992; 261(3): 1195-1199.
27. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 387(2): 356-363.
28. Mays DC, Hilliard JB, Wong DD, Chambers MA, Park SS, Gelboin HV, Gerber N. Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J Pharmacol Exp Ther 1990; 254: 720-731.
29. Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026-3031. (Pubitemid 27315056)
30. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-58.
31. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
32. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fund Clin Pharmacol 2004; 18: 621-629.
33. Marzolini C, Paus E, Buclin, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmcol Ther 2004; 75: 13-33. (Pubitemid 38130115)
34. De Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABC1) mediated transport of talinolol in Caco-2 cells. J Pharmaceut Sci 2007; 96: 2808-2817.
35. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, et al. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharma Res 2009; 26(3): 560.
36. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Patrice Jaillon P, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311-316.
37. Mooradian AD. Digitalis: An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendation. Clin Pharmacokinet 1988; 15: 165-179.
38. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003; 33:(suppl 2): 10-16.
39. Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001; 23(4): 369-373.
40. Bailey DG, Dresser GK. Interaction between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4: 281-297.
41. Libersa CC, Brique SA, Motte KB, Caron JF, Guédon-Moreau LM, Luc Humbert L, et al. Dramatic amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49: 373-337.
42. Le Goff-Klein N, Koffel JC, Jung L, Ubeaud G. In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice. Eur J Pharm Sci 2003; 18: 31-35. (Pubitemid 36120552)
43. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58(1): 56-60.
44. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66(2): 118-127.
45. Greenblatt DJ, Patki KC, von Moltke LL, Shader RI. Drug interactions with grapefruit juice: an update. J Clin Pyschopharmacol 2001; 21: 357-359.
46. Tomilson B, Chow MSS. Stereoselective interaction of manidipine and grapefruit juice: a new twist on an old tale. Br J Clin Pharmacol 2006; 61(5): 529-532.
47. Lundahl J, Regårdh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52(2): 139-145.
48. Bailey DG, Dresser GK. Interaction between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4: 281-297.
49. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-Co A reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-483.
50. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397-402. (Pubitemid 28214962)
51. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for National Cholesterol Education Programme Adult Treatment Panel II guidelines. Circulation 2004; 110: 227-239.
52. Taniguchi K, Ohtani H, Ikemoto T, Miki A, Hori S, Sawada Y. Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice. J Clin Pharm Therapeut 2007; 32: 457-459.
53. Bressier R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003; 78(12): 1564-1577.
54. Clotz U. Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 1998; 36(11): 581-585.
55. Row E, Brown SA, Stachulski AV, Lennard MS. Development of novel furanocoumarin dimmers as potent and selective inhibitors of CYP3A4. Drug Metab Dispos 2006; 34(2): 324-330. (Pubitemid 43145035)
56. Oda K, Yamaguchi Y, Yoshimura T, Wada K, Nishizono N. Synthetic models related to the furnanocoumarin, coumarin, and benzofuran dimers as potent and selective inhibitors of CYP3A4 activity. Chem Pharm Bull 2007; 59(9): 1419-1421.
57. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, et al. A furanocoumarin-free grapefruit juice establishes furanocourmarins as the selective mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83: 1097-1105.
58. Myung K, Narciso JA, Manthey JA. Removal of furanocoumarins in grapefruit juice by edible fungi. J Agric Food Chem 20008: 56: 12064-12068.
59. Uesawa Y, Mohri K. The use of heat treatment to eliminate drug interactions due to grapefruit juice. Biol Pharm Bull 2006; 29(110); 2274-2278.
60. Uesawa Y, Mohri K. UV-irradiated grapefruit juice loses pharmacokinetic interaction with nifedipine in rats. Biol Pharm Bull 2006; 29(6): 1286-1289.
61. Owira PMO, Ojewole JAO. Grapefruit juice improves glycemic control but exacerbates metformin-induced lactic acidosis in non-diabetic rats: Meth Findings Exper Clin Pharmacol 2009; 31(9): 563-570.
62. Fimognari FL, Pastorelli R, Incalzi RA. Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis). Diabetes Care 2006; 29(4): 950-951.
63. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfat C. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-438. (Pubitemid 38133916)
64. Florida Department of citrus: History of Dieting. Florida: Department of Citrus, Lakeland FL, 2003.
65. Fujioka K. Greenway F, Sheard J, Ying Y. The effects of grapefruit juice on weight and insulin resistance: relationship to metabolic syndrome. J Med Food 2006; 9(1): 49-54.
66. Adeneye AA. Hypoglycemic and hypolipidemic effects of methanol seed extract of Citrus paradisi Macfad (Rutaceae) in alloxan-induced diabetic Wistar rats. Nig Q J Hosp Med 2008; 18(4): 211-215.
67. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food 2005; 8(3): 281-290.
68. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005; 54(6): 1676-1683.
69. Punithavathi VR, Anuthama R, Prince PS. Combined treatment with naringin and vitamin C ameliorates streptozotocin-induced diabetes in male Wistar rats. J Appl Toxicol 2008; 28(6): 806-813.
70. Jung UJ, Lee MK, Jeong KS, Choi MS. Hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr 2004; 134: 2499-2503.
71. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol 2006; 38(7): 1134-1145.
72. Owira PMO. Grapefruit juice improves glycemic index and up-regulates expression of organic cation transporter protein (OCT1) in the rat. PhD thesis, 2009. University of KwaZulu-Natal.
73. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterisation of a small molecule AMPK activator that treats that treats key components of type2 diabetes and metabolic syndrome. Cell Metab 2006; 3: 403-416.
74. Seol W, Choi SH Moore DD. An orphan nuclear hormone receptor that lacks DNA binding domain and heterodimerises with other receptors. Science 1996; 272: 1336-1339.
75. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 amd Foxo1. J Biol Chem 2004; 279: 23158-23165. (Pubitemid 38685621)
76. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9(5): 407-416.
77. Mursu J, Voutilainen S, Nurmi T, Tuomainen TP, Kurl S, Salonen JT. Lavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2008; 100(4): 890-895.
78. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007; 85(3): 895-909.
79. Benavente-García O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008; 56(15): 6185-6205.
80. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003; 52(10): 2554-2561.
81. Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, Lo Curto RB. Biological effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco 1995; 50(9): 595-599.
82. Orallo F, Alvarez E, Basaran H, Lugnier C. Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch Pharmacol 2004; 370(6): 452-463.
83. Orallo F, Camiña M, Alvarez E, Basaran H, Lugnier C. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Med 2005; 71(2): 99-107.
84. Yamamoto M, Suzuki A, Hase T. Short-term effects of glucosyl hesperidin and hesperetin on blood pressure and vascular endothelial function in spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 2008; 54(1): 95-98.
85. Yamamoto M, Suzuki A, Jokura H, Yamamoto N, Hase T. Glucosyl hesperidin prevents endothelial dysfunction and oxidative stress in spontaneously hypertensive rats. Nutrition 2008; 24(5): 470-476.
86. Rajadurai M, Prince PS. Preventive effect of naringin on cardiac mitochondrial enzymes during isoproterenol-induced myocardial infarction in rats: a transmission electron microscopic study. J Biochem Mol Toxicol 2007; 21(6): 354-361. (Pubitemid 350210056)
87. Rajadurai M, Prince PS. Naringin ameliorates mitochondrial lipid peroxides, antioxidants and lipids in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res 2009; 23(3): 358-362.
88. Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D, et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 2005; 111(7): 835-838.
89. Piccirillo G, Magrì D, Matera S, Magnanti M, Pasquazzi E, Schifano E, et al. Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects. Transl Res 2008; 151(5): 267-272.
90. Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology 2008; 110(3): 145-152.
91. Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol 2008; 103(1): 82-87.